Disc Medicine, Inc. Board of Directors

Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for the treatment of erythropoietic porphyrias, including erythropoietic protoporphyria, X-linked protoporphyria, and diamond-blackfan anemia; DISC-0974 for the treatment of anemia of myelofibrosis, and anemia of chronic kidney disease; and DISC-3405 for the treatment of polycythemia vera, and other hematologic disorders. The company's preclinical programs include DISC-0998, for the treatment of anemia associated with inflammatory diseases. Disc Medicine, Inc. was founded in 2017 and is headquartered in Watertown, Massachusetts.

Ms. Jean M. Franchi CPA

Ms. Jean M. Franchi CPA

Chief Financial Officer

Dr. Rahul Khara J.D., Pharm.D.

Dr. Rahul Khara J.D., Pharm.D.

General Counsel, Compliance Officer & Secretary

Dr. Brian MacDonald ChB, MB, Ph.D.

Dr. Brian MacDonald ChB, MB, Ph.D.

Founder & Chair of Scientific Advisory Board

Mr. Jonathan Yu M.B.A.

Mr. Jonathan Yu M.B.A.

Chief Opearating Officer

Mr. Srikanth Venkatraman Ph.D.

Mr. Srikanth Venkatraman Ph.D.

Senior VP & Head of Chemistry

Ms. Hua Yang Ph.D.

Ms. Hua Yang Ph.D.

Senior Vice President & Head of Early Development and Clinical Pharmacology

Leaving Board of Directors Review Your about to visit the following url Invalid URL

Loading...
Comments


Comment created.